Ultra-Expensive Drugs And Medicare Part D: Spending And Beneficiary Use Up Sharply

So-Yeon Kang¹, Daniel Polsky², Jodi B Segal³, Gerard F Anderson⁴

Affiliations

¹ So-Yeon Kang (Soyeon.Kang@jhu.edu) is a PhD student in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, in Baltimore, Maryland.
² Daniel Polsky is the Bloomberg Distinguished Professor of Health Economics in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, and the Johns Hopkins Carey Business School.
³ Jodi B. Segal is a professor of medicine at the Johns Hopkins School of Medicine and a professor in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health.
⁴ Gerard F. Anderson is a professor of health policy and management and a professor of international health at the Johns Hopkins Bloomberg School of Public Health, a professor of medicine at the Johns Hopkins School of Medicine, and director of the Johns Hopkins Center for Hospital Finance and Management.

PMID: 34097507
DOI: 10.1377/hlthaff.2020.00896

Ultra-Expensive Drugs And Medicare Part D: Spending And Beneficiary Use Up Sharply

So-Yeon Kang et al. Health Aff (Millwood). 2021 Jun.

. 2021 Jun;40(6):1000-1005.

doi: 10.1377/hlthaff.2020.00896.

Authors

So-Yeon Kang¹, Daniel Polsky², Jodi B Segal³, Gerard F Anderson⁴

Affiliations

¹ So-Yeon Kang (Soyeon.Kang@jhu.edu) is a PhD student in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, in Baltimore, Maryland.
² Daniel Polsky is the Bloomberg Distinguished Professor of Health Economics in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, and the Johns Hopkins Carey Business School.
³ Jodi B. Segal is a professor of medicine at the Johns Hopkins School of Medicine and a professor in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health.
⁴ Gerard F. Anderson is a professor of health policy and management and a professor of international health at the Johns Hopkins Bloomberg School of Public Health, a professor of medicine at the Johns Hopkins School of Medicine, and director of the Johns Hopkins Center for Hospital Finance and Management.

PMID: 34097507
DOI: 10.1377/hlthaff.2020.00896

Abstract

The proliferation of "ultra-expensive" drugs has sparked debate on their sustainability and affordability. Medicare Part D's share of annual spending on these drugs increased by 1,170 percent between 2012 and 2018, largely because the number of beneficiaries receiving them increased during this period.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Ultra-Expensive Drugs And Medicare Part D: Spending And Beneficiary Use Up Sharply

Affiliations

Ultra-Expensive Drugs And Medicare Part D: Spending And Beneficiary Use Up Sharply

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical